Anaplastic carcinoma showing rhabdoid features combined with ovarian mucinous borderline cystadenoma: a case report and literature review

Tingting Sun¹, Liming Tian¹, Yunyun Guo¹, Yu Zheng¹, Linglong Ouyang¹, Xianbin Zhang², Yingrong Lai³ and Guofen Yang¹

Abstract
Anaplastic carcinoma in an ovarian tumor (ACOT) is rare. There have been a few controversial cases illustrating the clinical characteristics and prognostic factors of ACOT, which are not well known. A 60-year-old Chinese woman presented with a large pelvic tumor. A transvaginal ultrasound examination showed a large single ovarian cystic tumor with mural nodules and ascites. A gross ovarian mass with a size of approximately 20 × 10 × 15 cm³ was found. The content of the ovarian cyst was light yellow and chocolate-like, and a large grayish mural nodule of approximately 10 cm was found on the cyst wall. Histological diagnosis of ovarian mucinous borderline cystadenoma with a mural nodule of anaplastic carcinoma showing rhabdoid features and International Federation of Gynecology and Obstetrics (FIGO) stage IIIa was made. Fifteen months after surgery, the patient had received six courses of paclitaxel and carboplatin. She is still alive without any recurrence of the tumor. Findings from the present case suggest that patients with ACOT and FIGO stage IIIa would benefit from surgery and chemotherapy of paclitaxel and carboplatin. We also review the clinical features and survival rate of patients with ACOT using the Surveillance, Epidemiology, and End Result database, and summarize previously reported treatments.

¹Department of Gynecology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China
²Department of General Surgery, Shenzhen University General Hospital, Shenzhen, China
³Department of Pathology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China

Corresponding author:
Guofen Yang, Department of Gynecology, Sun Yat-sen University First Affiliated Hospital, No. 58 Zhong Shan II Road, 510080, Guangzhou, China.
Email: yangguof@mail.sysu.edu.cn
Introduction

Mural nodules are rare, and are found in the wall of various ovarian mucinous tumors (including malignant, borderline, and benign tumors). Mural nodules can be classified into sarcoma-like mural nodule (SLMN), anaplastic carcinoma, and true sarcoma. As a malignant nodule, anaplastic carcinoma in an ovarian tumor (ACOT) is an exceedingly rare type, which was first reported in 1982. ACOT is histologically divided into three patterns of rhabdoid, spindle (sarcomatoid), and pleomorphic (combined sarcomatoid and rhabdoid) patterns. These three histological patterns of ACOT have no adverse effects on prognosis, but diversity of the tumor causes a challenging histological diagnosis.

Because of the rarity of this disease, there have been a few controversial case reports on ACOT. To date, the clinical characteristics, prognostic factors, and standardized treatments of patients with ACOT are not well known, greatly limiting the diagnosis and treatment of this disease.

We report a 60-year-old woman with ACOT. Microscopic and immunohistochemical findings of this case were analyzed, and the clinical treatments and outcomes of the patient are described. Moreover, we reviewed the clinical features and survival rate of patients with ACOT using the Surveillance, Epidemiology, and End Result (SEER) database, and summarized previously reported treatments. These results may help patients and gynecologists to better understand this disease and make informed decisions for treatment of patients with ACOT.

Case presentation

This case report was prepared following the CARE Guidelines. A 60-year-old Chinese woman with a large pelvic tumor was transferred to the First Affiliated Hospital of Sun Yat-sen University on the suspicion of ovarian malignancy in April 2019. She showed increased abdominal fullness, but no fever, abdominal pain, nausea, vomiting, vaginal bleeding, or dysuria.

A transvaginal ultrasound examination showed a large, single, ovarian, cystic tumor (186 × 103 × 151 mm³) containing anechoic and solid areas. An abundant blood flow signal was observed in the solid part of the tumor (Figure 1). These examination results suggested the presence of a malignant tumor, and therefore, the patient underwent exploratory laparotomy. Computed tomography and magnetic resonance imaging were not performed because of financial constraints. Serum levels of cancer antigen (CA) 125 and CA19-9 were 283.30 U/mL and 2470.74 U/mL, respectively, and both were above the normal range (cut-off values for CA125 and CA19-9: 35 U/mL and 35 U/mL, respectively) and kept increasing. During surgery, a gross ovarian mass (approximately 20 × 10 × 15 cm³) with a smooth outer surface was found. The content of the left ovarian cyst was light yellow and chocolate-like, and a large grayish mural nodule of approximately 10 cm in diameter was found on the cyst wall. Resection of the ovarian mass was assessed by intraoperative frozen section analysis, and the patient was primarily diagnosed with ovarian mucinous borderline cystadenoma. Finally, the patient had...
optimal debulking of the tumor performed, which included bilateral salpingo-oophorectomy hysterectomy, omentectomy, appendicectomy, resection of a superficial tumor of the bladder, resection of a tumor in the Douglas pouch, and peritoneal multipoint biopsy.

A histopathological examination showed cells with dysplasia and cells with a diffuse patchy growth pattern, which were diagnosed as ovarian mucinous borderline cystadenoma and anaplastic carcinoma, respectively (Figure 2). Nodules displayed a rhabdoid pattern, diffuse arrangement of cells with abundant, bright, and eosinophilic cytoplasms, and one or more prominent nucleoli with an atypical ovoid and eccentric shape. The mural nodules were positive for cytokeratin, epithelial membrane antigen (EMA), vimentin, desmin, integrase interactor 1 (INI-1), P53 (90%), and Ki-67 (50%) (Figure 3). These nodules were negative for Wilms tumor 1 (WT-1), paired box 8 (PAX8), estrogen receptor (ER), progesterone receptor (PR), cluster of differentiation 10 (CD10), melanosome (HMB-45), S-
100, actin, myogenin, myogenic differentiation 1 (MyoD1), CD56, synaptophysin (Syn), chromogranin A (CgA), and inhibin-α. The same lesions were also observed in the left oviduct, the omentum, and the surface of the bladder. A small number of atypical cells were identified in the ascites. Therefore, we diagnosed the patient as having an anaplastic carcinoma in ovarian mucinous borderline cystadenoma with International Federation of Gynecology and Obstetrics (FIGO) stage IIIa. She received six courses of paclitaxel (240 mg) and carboplatin (120 mg) with an interval of 3 to 4 weeks.

After the adjuvant chemotherapy, the patient developed mild complications of chemotherapy, such as hair loss and leukopenia. Fifteen months after surgery, the patient is still alive without any recurrence of the tumor (Figure 4).

Discussion

ACOT is an infrequent disease, and can arise in any ovarian mucinous tumor. During the past decades, only a few cases of ACOT have been reported. Further investigations on the clinical characteristics of ACOT are required to better understand this disease and examine effective treatments.

We report a 60-year-old Chinese patient with FIGO stage IIIA and ACOT. To investigate clinical characteristics of patients with ACOT, a dataset of ACOT from 2004 to 2013 was extracted from the SEER database using the following classification code of International Classification of Diseases for Oncology, the third Edition (ICD-O-3): primary tumor originated from ovarian (C569) and anaplastic carcinoma (8021) (Table 1). A total of 140,487 patients with ovarian mucinous tumors were identified. Figure 3 shows the microscopic and immunohistochemical findings of the mural nodules.
tumors were recruited, among whom 177 (1.26%) patients with ACOT were chosen to include in this report. The clinical characteristics of the 177 included patients are listed in Table 1. We found that 77.4% (137/177) of the patients with ACOT were diagnosed in the advanced stage. Similar to other types of general ovarian cancer, detecting ACOT cases in the early stage is a challenge. In contrast, Provenza et al.\(^3\) reviewed published case reports of ACOT and showed that only 22.2% (4/18) of patients were in the advanced stage. Despite clinical data of ACOT reported in the literature, statistical significance was limited by the small cohort size.

We report a case of ACOT, which expands our knowledge regarding the behavior and morphological spectrum of ACOT. Mural nodules can present with any ovarian mucinous tumor (benign, borderline, or malignant), and are commonly divided into SLMN, ACOT, and true sarcoma.\(^1\) Distinguishing the three types of lesions is difficult, but important, because they differ in overall survival time and prognosis.\(^1\) Immunohistochemistry can be used as an identification method because of the morphological similarity of these mural nodules.\(^1\) ACOT nodules tend to stain strongly for cytokeratin and are negative for vimentin, whereas SLMN and

**Figure 4.** Levels of tumor biomarkers during treatment. (a) Cancer antigen (CA) 125 levels during treatment; (b) CA19-9 levels during treatment.

**Table 1.** Clinical characteristics of patients with anaplastic carcinoma in an ovarian tumor.

| Variable | Patients’ characteristics (n = 177) |
|----------|----------------------------------|
| Age, median (IQR), years | 64 (52–74) |
| Marital status at diagnosis, n (%) |  |
| Single | 25 (14.1) |
| Married | 89 (50.3) |
| Separated | 3 (1.7) |
| Divorced | 12 (6.8) |
| Widowed | 45 (25.4) |
| Unknown | 3 (1.7) |
| Race, n (%) |  |
| White | 163 (92.1) |
| Black | 5 (2.8) |
| American Indian/Alaskan native | 2 (1.1) |
| Asian or Pacific Islander | 7 (4) |
| FIGO stage, n (%) |  |
| I | 24 (13.6) |
| II | 16 (9) |
| III | 126 (71.2) |
| IV | 11 (6.2) |
| Operation, n (%) |  |
| No operation | 49 (27.7) |
| Operation | 118 (66.7) |
| Unknown | 10 (5.6) |
| Survival, n (%) |  |
| Alive or dead due to cancer | 135 (76.3) |
| Dead | 20 (11.3) |
| Not the first tumor | 22 (12.4) |

IQR, interquartile range; FIGO, International Federation of Gynecology and Obstetrics.
Table 2. Summary of cases of anaplastic carcinoma in a mucinous cystic ovarian tumor.

| Author                  | Age (years) | FIGO stage | Surgery       | Disease      | Size of nodule (cm) | Adjuvant therapy | Chemotherapy regimen (cycles) | Follow-up (months) |
|-------------------------|-------------|------------|---------------|--------------|---------------------|------------------|-------------------------------|-------------------|
| Prat et al. 2           | 46          | Ia         | TH+BSO+OM     | Carcinoma    | 1.7                 | Chemo            | Alkeran                       | DOD (4)           |
|                         | 46          | Ia         | TH+BSO        | Carcinoma    | 4.5                 | –                | –                             | DOD (7)           |
|                         | 72          | III        | TH+BSO+OM     | Carcinoma    | 2                   | Chemo            | Adriamycin (6); Cyclophosphamide + cisplatin (9); Cyclophosphamide (12) | NED (18)         |
| Czernobilisky et al. 13 | 75          | Ia         | TH+BSO+OM+LN  | Carcinoma    | 3                   | Rad              | –                             | NED (12)          |
| Yamana et al. 14        | 27          | Ia         | TH+BSO        | Carcinoma    | –                   | None             | –                             | DOD (120)         |
| Hayman et al. 7         | 50          | Ia         | TH+BSO        | Carcinoma    | 4                   | None             | –                             | DOD (12)          |
| Fujii et al. 15         | 29          | Ia         | TH+BSO        | Borderline   | 2                   | None             | –                             | NED (22)          |
| Chan et al. 16          | 30          | Ib         | TH+BSO+OM     | Borderline   | 2                   | Chemo            | Cisplatin + cyclophosphamide  | NED (4)           |
| Kessler 17              | 22          | Ia         | TH+BSO        | Carcinoma    | –                   | –                | –                             | –                 |
| Nichols et al. 11       | 66          | Ia         | TH+BSO+OM     | BIEC         | 0.5                 | Chemo            | Cisplatin/cytoxan (6)         | NED (12)          |
|                         | 74          | Ia         | TH+BSO+OM     | BIEC         | 4                   | Chemo            | Alkeran (2)                  | DOD (12)          |
|                         | 45          | Ia         | TH+USO        | Carcinoma    | 4                   | None             | –                             | NED (47)          |
| Sondergaard et al. 4    | 66          | Ic         | TH+BSO+OM+A   | Carcinoma    | 12                  | –                | –                             | DOD (3)           |
|                         | 29          | Ia         | TH+BSO        | Carcinoma    | 1.5                 | –                | –                             | NED (24)          |
|                         | 37          | Ia         | TH+BSO+OM+A   | Borderline   | 22                  | –                | –                             | NED (18)          |
| Tsuruchi et al. 12      | 18          | Ib         | TH+BSO+OM     | Carcinoma    | 4.5                 | Chemo            | Cisplatin + adriamycin + cyclophosphamide (1); cisplatin + adriamycin (9) | DOD (41)          |
| Hellemans et al. 18     | 38          | Ic         | TH+BSO+OM+LN  | Carcinoma    | –                   | None             | –                             | NED (30)          |
| Nakamura et al. 19      | 28          | Ia         | TH+BSO+OM+LN  | Carcinoma    | 1                   | None             | –                             | NED (24)          |
| Baergen et al. 20       | 37          | III        | TH+BSO+OM     | Carcinoma    | 1                   | Chemo            | –                             | DOD (6)           |
| Hillesheim et al. 21    | 40          | Ia         | TH+BSO+OM     | Carcinoma    | 8                   | –                | –                             | NED (12)          |
| Yamazaki et al. 9       | 45          | Ia         | TH+BSO+OM     | Borderline   | 3.6                 | None             | –                             | NED (15)          |
| Mhawech-Faucceglia et al. | 36        | Ia         | TH+BSO+OM     | Borderline   | 2.2                 | None             | –                             | DOD (3)           |
| Okumura et al. 22       | 53          | Ib         | TH+BSO+OM     | Borderline   | 4                   | Chemo            | Paclitaxel + carboplatin (6)  | NED (36)          |

(continued)
sarcomas are negative for cytokeratin, but positive for vimentin. As reported previously, in ACOT nodules, cytokeratin (AE1/3) and CAM5.2 are typically positive, vimentin, desmin, and PAX8 are variable, and ER and PR are usually negative. In our case, the nodules were positive for cytokeratin (AE1/3), epithelial membrane antigen, vimentin, and integrase interactor 1 (Figure 3), and negative for Wilms tumor 1, PAX-8, ER, and PR. This led to the diagnosis of ACOT.

The foci/nodules of ACOT can be divided into rhabdoid, spindle, and pleomorphic patterns. Our case was rhabdoid ACOT, and showed diffuse arrangement of large cells containing one or more prominent nucleoli, and a bright, eosinophilic cytoplasm and eccentric nuclei. Although these categories of foci/nodules do not have an effect on patients’ outcomes and prognosis, they can make histological diagnosis difficult.

Currently, there is no standard treatment for ACOT owing to the lack of knowledge on ACOT. Previous reports have highlighted the importance of adjuvant chemotherapy in postoperative management of ACOT. We reviewed and summarized previous literature on ACOT (Table 2), and found that adjuvant chemotherapy was used in postoperative management for some stage I patients and most patients at a higher stage (stage II, III, or IV). Among cases of ACOT in the literature, regarding the 22 patients in stage I, two of four patients died after chemotherapy, three of eight patients died without chemotherapy, one patient with radiation treatment was still alive at 12 months, and information on chemotherapy was not available for nine patients. Therefore, determining whether adjuvant chemotherapy improves the overall survival rate of stage I patients is difficult. Furthermore, platinum-based chemotherapy was used for most of the ACOT cases (7/9) and resulted in favorable outcomes.

| Author                | Age (years) | FIGO stage | Surgery | Disease | Size of nodule (cm) | Adjuvant therapy | Chemotherapy regimen (cycles) | Follow-up (months) |
|-----------------------|-------------|------------|---------|---------|---------------------|------------------|-------------------------------|--------------------|
| Ardakani et al.        | 48          | IV         | –       | Carcinoma | 1.4                 | –                | AWD (10)                      | NED (10)           |
|                       | 30          | IIIB       | –       | Carcinoma | 0.5                 | –                | –                             | –                  |
|                       | 68          | Ia         | BSO     | Carcinoma | 4.5                 | Chemo            | Paclitaxel+carboplatin (6)    | NED (6)            |
|                       | 43          | Ic         | BSO     | Carcinoma | 0.5                 | –                | –                             | –                  |
|                       | 37          | IIIb       | TH      | Carcinoma | 1.9                 | Chemo            | Paclitaxel+carboplatin (6)    | –                  |
|                       | 48          | Ia         | BSO     | Carcinoma | 0.8                 | –                | –                             | –                  |
|                       | 64          | Ic         | TH      | Carcinoma | 3.5                 | –                | –                             | –                  |

FIGO, International Federation of Gynecology and Obstetrics; TH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; OM, omentectomy; Chemo, chemotherapy; DO, died of disease; NED, no evidence of disease; USO, unilateral salpingo-oophorectomy; LN, lymph node sampling; Rad, radiation therapy; BIEC, borderline tumor with intraepithelial carcinoma; A, appendectomy; AWD, alive with disease.
clinical outcomes. Among these seven patients, five survived without evidence of disease and two died of the disease (Table 2). In the present ACOT case, platinum-based chemotherapy was performed. To date, the current patient is still alive without relapse. Because the therapeutic regimens were not available for most cases in the previous reports, more investigation on treatment for ACOT is required.

We also analyzed the survival data of ACOT cases from the SEER database (Figure 5). Statistical analysis was carried out using IBM SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). We found that patients with ACOT in stage I had a high rate of overall survival. This finding is consistent with a previous report in which patients without metastasis or infiltration beyond the ovaries showed a favorable prognosis. Provenza et al. also found that unruptured stage I cases had a better prognosis than cases at other stages.

**Conclusion**

We report a patient with ACOT and FIGO stage IIIa. Our findings suggest that these patients would benefit from surgery and adjuvant chemotherapy of paclitaxel and carboplatin. This is the first study to investigate the clinical features and survival rate of patients with ACOT using the SEER database. Using data from a literature review, effective treatments for ACOT were also summarized. Our research...
findings may help patients and gynecologists to make informed decisions for treatment of patients with ACOT.

**Ethics statement**

The clinical data were approved by the Ethics Committee of the First Affiliated Hospital of Sun Yetsen University (ethics approval no. 308-2016-03-01). Consent for treatment was obtained from the patient and written informed consent for publication was signed by the patient. Part of the original data of our study were provided by the SEER database.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This study was funded by grants from the National Natural Science Foundation of China (No. 81772769), the Guangzhou Science, Technology and Innovation Commission (No. 201704020125), the Guangdong Medical Science and Technology Research Fund (No. 2019422101535694), and China Post-doctoral Science Foundation (No. 227241).

**ORCID iD**

Guofen Yang https://orcid.org/0000-0002-1199-4624

**References**

1. Mhawech-Fauceglia P, Ramzan A, Walia S, et al. Microfocus of Anaplastic Carcinoma Arising in Mural Nodule of Ovarian Mucinous Borderline Tumor With Very Rapid and Fatal Outcome. *Int J Gynecol Pathol* 2015; 35: 348–351. DOI: 10.1097/pgp.000000000000252.
2. Prat J, Young RH and Scully RE. Ovarian mucinous tumors with foci of anaplastic carcinoma. *Cancer* 1982; 50: 300–304. DOI: 10.1002/1097-0142(19820715)50:2<300::aid-cncr2820500222;2.0.co;2-e.
3. Provenza C, Young RH and Prat J. Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. *Am J Surg Pathol* 2008; 32: 383–389. DOI: 10.1097/PAS.0b013e3181451b93.
4. Sondergaard G and Kaspersen P. Ovarian and extraovarian mucinous tumors with solid mural nodules. *Int J Gynecol Pathol* 1991; 10: 145–155. DOI: 10.1097/00004347-199104000-00003.
5. Rodriguez IM and Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. *Am J Surg Pathol* 2002; 26: 139–152. DOI: 10.1097/00000478-200202000-00001.
6. Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. *Headache* 2013; 53: 1541–1547. DOI: 10.1111/head.12246.
7. Hayman JA and Ostor AG. Ovarian mucinous tumour with a focus of anaplastic carcinoma: a case report. *Pathology* 1985; 17: 591–593. DOI: 10.3109/00313028509084758.
8. Zheng J, Geng M, Li P, et al. Ovarian mucinous cystic tumor with sarcoma-like mural nodules and multifocal anaplastic carcinoma: a case report. *Int J Clin Exp Pathol* 2013; 6: 1688–1692.
9. Yamazaki H, Matsuzawa A, Shoda T, et al. Ovarian mucinous cystic tumor of borderline malignancy with a mural nodule of anaplastic spindle cell carcinoma: a case report. *J Ovarian Res* 2013; 6: 86–90. DOI: 10.1186/1757-2215-6-86.
10. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1975-2016), National Cancer Institute, DCCPS, Surveillance Research Program, released July 2019, based on the April 2019 submission.
11. Nichols GE, Mills SE, Ulbright TM, et al. Spindle cell mural nodules in cystic ovarian mucinous tumors. A clinicopathologic and immunohistochemical study of five cases. *Am J Surg Pathol* 1991; 15: 1055–1062. DOI: 10.1097/00000478-199111000-00004.
12. Tsuruchi N, Kaku T, Kinoshita H, et al. Ovarian mucinous cystadenocarcinoma with sarcoma-appearing mural nodule of
10

Journal of International Medical Research

anaplastic carcinoma. *Gynecol Oncol* 1993; 50: 259–263. DOI: 10.1006/gyno.1993.1204.

13. Czernobilsky B, Dgani R and Roth LM. Ovarian mucinous cystadenocarcinoma with mural nodule of carcinomatous derivation. A light and electron microscopic study. *Cancer* 1983; 51: 141–148. DOI: 10.1002/1097-0142(19830101)51:1<141::aid-cncr2820510128>3.0.co;2-7.

14. Yamana K, Kinoshita T, Nakano R, et al. Anaplastic giant cell tumor with mucinous cystadenocarcinoma of the ovary. Origin of the giant cells. *Acta Pathol Jpn* 1984; 34: 399–402. DOI: 10.1111/j.1440-1827.1984.tb07567.x.

15. Fujii S, Konishi I, Kobayashi F, et al. Sarcoma-like mural nodules combined with a microfocus of anaplastic carcinoma in mucinous ovarian tumor. *Gynecol Oncol* 1985; 20: 219–233. DOI: 10.1016/0090-8258(85)90145-3.

16. Chan YF, Ho HC, Yau SM, et al. Ovarian mucinous tumor with mural nodules of anaplastic carcinoma. *Gynecol Oncol* 1989; 35: 112–119. DOI: 10.1016/0090-8258(89)90024-3.

17. Kessler E. Sarcoma-like mural nodules with foci of anaplastic carcinoma in ovarian mucinous tumor: clinical, histological and immunohistochemical study of a case and review of the literature. *Surg Pathol* 1990; 3: 211–219.

18. Hellemans H, Moerman P, Timmerman D, et al. Anaplastic nodules in an ovarian mucinous tumor. Case report and literature review. *Eur J Gynaecol Oncol* 1998; 19: 529–533.

19. Nakamura E, Shimizu M, Mikami Y, et al. Ovarian mucinous cystadenocarcinoma with malignant mural nodules. *Pathol Int* 1998; 48: 645–648. DOI: 10.1111/j.1440-1827.1998.tb03964.x.

20. Baergen RN and Rutgers JL. Mural nodules in common epithelial tumors of the ovary. *Int J Gynecol Pathol* 1994; 13: 62–72. DOI: 10.1097/00004347-199401000-00008.

21. Hillesheim PB and Farghaly H. Anaplastic spindle cell carcinoma, arising in a background of an ovarian mucinous cystic tumor: a case report with clinical follow up, review of the literature. *Int J Clin Exp Pathol* 2010; 3: 808–811.

22. Okumura T, Muronosono E, Tsubuku M, et al. Anaplastic carcinoma in ovarian seromucinous cystic tumor of borderline malignancy. *J Ovarian Res* 2018; 11: 77–82. DOI: 10.1186/s13048-018-0449-1.

23. Ardakani NM, Giardina T, Amanuel B, et al. Molecular Profiling Reveals a Clonal Relationship Between Ovarian Mucinous Tumors and Corresponding Mural Carcinomatous Nodules. *Am J Surg Pathol* 2017; 41: 1261–1266. DOI: 10.1097/PAS.0000000000000875.

24. Kihara T, Komatsu M, Sakuma T, et al. Anaplastic Carcinoma Arising From Ovarian Mucinous Adenocarcinoma With Massive Cardiopulmonary Metastasis: An Autopsy Case Report. *J Obstet Gynaecol Can* 2019; 41: 72–75. DOI: 10.1016/j.jogc.2018.07.014.